This article highlights recent developments in GLP-1 agonist formulations and delivery methods, including advanced injectable formulations (eg, prolonged release), novel oral delivery systems (eg, buccal tablets), and topical formulations (eg, transdermal patches)
or Download and complete the form, then submit it via fax at 1-800-FDA-0178
This mechanism reduces hunger but also means dense or high-fat protein shakes sit in your stomach longer
Ensacove, an orally available tyrosine kinase inhibitor, addresses ALK-positive NSCLC by disrupting ALK-mediated signaling, in turn blocking the hyperactive growth and proliferation typical of cancer cells
The new WeightWatchers GLP-1 Program, which was developed by WeightWatchers team of obesity specialists, clinicians, behavior-change scientists, dietitians and fitness experts, solves a gap in the market as members navigate life on new weight loss medications